Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Drugmakers Show Restraint on Price Increases in New Trump Era
Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...
Big Pharma has already raised the prices of hundreds of drugs this year
Pharmaceutical companies have already raised the price of over 800 brand-name prescription drugs this year. Nearly all the ...
Eli Lilly price target lowered to $1,190 from $1,250 at Citi
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Eli Lilly price target lowered to $970 from $1,000 at Wells Fargo
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
Fact Check: Message about insulin price increase announcements originated as satire
A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...